Media Contact

Ms. Pinchun Chou

Tel: +886-2-8978-6488 ext.669

Ms. Lindsay Hou

Tel: +886-2-8978-6488 ext.667

RSS Subscription
  NAND Flash  
  Consumer Electronics  
  Green Energy  
  Internet of Things  
  Automotive Electronics  
  Innovative Technological Applications  

Press Release

Global Market for Breast Cancer Drugs to Grow at a CAGR of 9.3% in the 2016~2013 Period as New Drugs Enter the Market, Says TrendForce

Monday , 04 / 17 / 2017 [ Analysts: Sean Liu ]

The global market for breast cancer drugs is growing steadily due to rising patient population, introduction of new drugs and sales growth of Perjeta and Kadcyla. The latest biotechnology market report from TrendForce states that the global market scale of breast cancer drugs reached US$11.97 billion in 2016 and is forecast to expand at a CAGR of 9.3% to US$22.35 billion in 2023.

Based on the surface antigens of tumor cells, breast cancers are classified into three subtypes – HER2-positive, HR-positive and triple-negative. The market for drugs treating HER2-positive breast cancers has been growing rapidly, driven by the growing sales of Kadcyla and Perjeta worldwide. The global market scale of HER2-positive drugs was around US$7.41 billion in 2016, and TrendForce projects that it will arrive at U$12.42 billion in 2023 with the CAGR during the 2016~2023 period at about 7.7%.

Likewise, the market for HR-positive and triple-negative breast cancer drugs will keep booming over the next several years as sales of Ibrance are expected to remain robust and new drugs such as CDK4/6 inhibitors enter the market. According to TrendForce’s analysis, the global market scale of HR-positive and triple-negative breast cancer drugs came to US$4.56 billion in 2016 and is going to expand at a CAGR of 11.8% to reach US$9.93 billion in 2023.

Sean Liu, TrendForce’s associate research manager for biotechnology industry, pointed out that many pharmaceutical companies are attracted by the opportunities in the breast cancer market, which has an enormous patient population. “A large share of the numerous clinical solutions are for treating HER2-positive and the HR-positive subtypes,” said Liu. “Recently, pharmaceutical companies have recognized that there is unmet medical need for effective treatments related to triple-negative and BRCA subtypes of breast cancer. PI3K and PARP inhibitors, along with various new drugs, have been developed to address this demand. These drugs are now entering phase III clinical trials and are expected to arrive on the market within these three years.”

To keep updated with our press releases, please follow our social media pages. facebookGoogle+TwitterLinkin

Biotechnology Innovative Technological Applications

TrendForce Press Center Copyright Notice
TrendForce grants you a limited license to use and/or republish any of the press releases on TrendForce Press Center for any legitimate media purpose (including copying and redistributing the content of press releases in any format and via any outlets), provided that you follow these license terms:

1. Reference TrendForce as the source on your works, or include a hyperlink to the original release on the TrendForce site.
2. Do not modify any press release wording, or maliciously alter its related information. Users are subject to any civil or criminal liabilities if the information displayed in the copy or redistribution of press releases is inconsistent with the original materials on TrendForce Press Center.
3. Do not modify or add hyperlinks, including but not limited to adlinks, within the press release. The authorization of press releases on TrendForce Press Center does not grant users the right to suggest, approve or endorse their value-added derivatives on behalf of this body.

If your citations of press releases contain mistakes and/or have information missing, TrendForce may, in its sole discretion, direct you to remove the content distributed via TrendForce from your site at any time and for any reason, and you agree to comply with such request.